One such gene, CERS1, was utilized to develop a drug combination strategy against cisplatin resistance, which was validated in an osteosarcoma‐resistant cell model, elucidating its molecular mechanism in combating drug resistance. This evidence concerns the gene CERS1 and osteosarcoma.